Analyzing the Contradiction: U.S. Funding WHO and the Paradox of Indian Pharmaceuticals
The United States is one of the largest contributors to the World Health Organization (WHO), funding initiatives that heavily depend on affordable, generic medications from India. Despite supporting global health programs with Indian generics, the U.S. remains reluctant to embrace these same cost-effective solutions domestically. This paradox highlights the influence of pharmaceutical lobbying and raises ethical questions about healthcare affordability and access. The contrast between supporting international health initiatives and restricting domestic use of Indian generics calls for a reevaluation of U.S. healthcare policies to better align with global health standards and patient needs.